The number of lawsuits filed in the Philadelphia mass tort litigation regarding Xarelto side effects has grown to nearly 350 individual cases, according to data from the Philadelphia Court of Common Pleas.
About Xarelto Lawsuits
Xarelto is a prescription anticoagulant (also known as blood thinner) which was approved by the FDA in 2011 and has had commercial success in the US market ever since.
The drug is typically prescribed to prevent certain types of blood clots including deep vein thrombosis and pulmonary embolism. Xarelto is also commonly prescribed to prevent the formation of blood clots in patients that have gone under a knee or hip replacement surgery.
However, as many recent studies have shown, Xarelto may be associated with serious side effects including irreversible internal bleeding. These findings have led many to file lawsuits against the companies responsible for producing and distributing Xarelto in America. In addition to other allegations, these complaints assert that the companies acted negligently by failing to warn about the risks associated with the drug.
On January 22nd, 2015 the Philadelphia Court of Common Pleas consolidated several lawsuits pertaining to the allegedly dangerous side effects associated with Xarelto.
There were initially 75 separate cases consolidated in the mass tort litigation in Philadelphia, however the total number of cases involved has continuously grown since then and now includes almost 350 complaints.
Additionally, more than 400 Xarelto lawsuits have been consolidated in a multidistrict litigation based in the U.S. District Court for the Eastern District of Louisiana.
Representation For Plaintiffs In Xarelto Litigation
“Several new studies have been released within the last few months linking Xarelto to potentially dangerous side effects which could lead to injury or death,” commented Stephen A. Sheller, Esq.
“Our firm is currently helping plaintiffs who wish to file complaints in the Philadelphia Mass Tort Group, as well as those who wish to file a claim in the MDL based in Louisiana.”
Please direct all questions about this article and the Xarelto litigation to Marc Goldich at 866-425-8902.